Will NeuroSense Therapeutics stock go up?

According to Danelfin AI, NeuroSense Therapeutics has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.71%) is -5.11% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for NeuroSense Therapeutics stock?

The NeuroSense Therapeutics target price is $0.71 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold NeuroSense Therapeutics stock right now?

NeuroSense Therapeutics has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (45.71%) is -5.11% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether NeuroSense Therapeutics stock is a good buy .

Is NeuroSense Therapeutics undervalued right now?

Based on analysts, the average price target downside for NeuroSense Therapeutics is 0.00% (1Y). According to Danelfin AI, NeuroSense Therapeutics has today an AI Score of 3/10 (Sell Rating).

What was the price range of NeuroSense Therapeutics stock over the past 12 months?

The NeuroSense Therapeutics stock price range over the past 12 months has been $0.69 - $2.35.

What is going on with NeuroSense Therapeutics stock in the last 3 months?

The NeuroSense Therapeutics stock performance in the last quarter has been -6.71%.

Does NeuroSense Therapeutics offer dividend payments?

No, NeuroSense Therapeutics does not currently pay dividends.

What is the current market capitalization of NeuroSense Therapeutics?

NeuroSense Therapeutics's market cap is $25.03M, as of 2026-07-03 08:00.

Neurosense Therapeutics Ltd (NRSN) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

NRSN AI-Powered Stock Analysis

AI Score Explanation

AI Score

Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Neurosense Therapeutics Ltd today receives an AI Score of 3/10, which translates to a Sell rating. The stock has a 46% probability of outperforming the market in the next 3 months, which is 5% lower than the average probability of any stock (51%). Among positive contributors, the Technicals Impact (Long Tail) adds +1.47% to the probability, while ATR (14d Volatility) in the bottom 10% boosts it by +1.35%, and the Chart Pattern (180d) contributes +0.83%. On the negative side, the Fundamentals Impact (Long Tail) detracts -2.94%, the Fear & Greed Index at 31 (extreme fear) reduces probability by -1.40%, and the Chart Pattern (120d) subtracts -1.20%. The Biotechnology industry also weighs down the outlook by -0.94%. Notable data points include Institutional Ownership in the bottom 10% at just 1.07%, indicating very low confidence from large investors, which detracts -1.16%. Maximum Volatility ranks in the top 20% (value 9.59), signaling high extreme risk and reducing probability by -1.09%. Similarly, Normalized ATR (50d) in the top 20% (10.77%) reflects elevated volatility, subtracting -0.68%. Conversely, low volatility measures like ATR (14d), ATR (90d), and ATR (180d) all sit in the bottom 10%, providing positive contributions. Overall, the stock faces headwinds from weak fundamentals, extreme fear sentiment, high volatility, and low institutional ownership, while benefiting from low short-term volatility and some technical patterns. The net negative effect of signals explains the Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+0.68%
Direction and strength of recent price movements
Volatility+0.08%
How much the stock price tends to fluctuate

Valuation-2.94%
How the stock is priced relative to its fundamentals
Sentiment-2.93%
How analysts and the market view the stock

NRSN probability advantage of beating the market (3M):

-5.11%

AI Score

Sell

NeuroSense Therapeutics (NRSN) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -5.11% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of NRSN (45.71%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
NRSN probability advantage of beating the market (3M)-5.11%
NRSN probability of beating the market (3M)45.71%

NRSN probability advantage of beating the market (3M): -5.11%

The AI-powered overall analysis of NeuroSense Therapeutics (NRSN) is based on the 20 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of NRSN:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-2.94%
Technical	Technicals Impact (Long Tail)	-	N/A	+1.47%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.40%
Technical	ATR (14d Volatility)	0.08	N/A	+1.35%
Technical	Chart Pattern (120d)	figure_89	N/A	-1.20%
Sentiment	Institutional Ownership	1.07%	N/A	-1.16%
Technical	Maximum Volatility	9.59%		-1.09%
Sentiment	Industry (GICS)	Biotechnology	N/A	-0.94%
Technical	Chart Pattern (180d)	figure_48	N/A	+0.83%
Technical	Chart Pattern (504d)	figure_91	N/A	+0.81%
Technical	Upgrade to unlock			-0.68%
Sentiment	Upgrade to unlock			+0.56%
Technical	Upgrade to unlock			-0.44%
Technical	Upgrade to unlock			+0.43%
Technical	Upgrade to unlock			-0.40%

Rest of Alpha Signals: -0.31%

NRSN probability advantage of beating the market (3M)Total:-5.11%
NRSN AI Score

Significant changes Vs previous day

NRSN Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$0.71
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

NRSN Proven Sell Signal & Price Forecast

This is the price chart for NRSN from January 2, 2026 until today. The chart indicates, in red, the 57 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

NRSN Average Past Performance & Loss Rate

Three months after its 481 Sell signals since July 2026, NRSN had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

481 Past NRSN Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-22.97%
Average Alpha				-35.21%
Loss Rate (% Negative Perf.)				79.73%
% Negative Alpha				84.59%

NRSN Frequently Asked Questions

Will NeuroSense Therapeutics stock go up?
According to Danelfin AI, NeuroSense Therapeutics has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.71%) is -5.11% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for NeuroSense Therapeutics stock?
Is it a good time to buy, sell, or hold NeuroSense Therapeutics stock right now?
Is NeuroSense Therapeutics undervalued right now?
What was the price range of NeuroSense Therapeutics stock over the past 12 months?
What is going on with NeuroSense Therapeutics stock in the last 3 months?
Does NeuroSense Therapeutics offer dividend payments?
What is the current market capitalization of NeuroSense Therapeutics?

Neurosense Therapeutics Ltd Company Profile

NeuroSense Therapeutics Ltd., a biotechnology company in its clinical phase, directs its vision towards discovering and fashioning remedies for individuals plagued by disabling neurodegenerative disorders both within the United States and globally. Its primary product, PrimeC, is an oral formulation designed with extended-release capabilities. It merges a fixed dosage of two components, ciprofloxacin and celecoxib, aiming to treat the afflictions of amyotrophic lateral sclerosis.

Additionally, the company’s drug development pipeline in cut-and-dried stages incorporates StabiliC, aimed at tackling Parkinson's disease, alongside CogniC manufactured with the purpose of addressing Alzheimer’s disease. The initiation chapter of NeuroSense Therapeutics Ltd. was written in 2017. The nerve center steering this entity pulses from Herzliya, Israel.

Sector:
Country:Israel
Industry:
Address:11 Hamenofim St., Building B, NaN, Herzliya
Employees:16
Website:neurosense-tx.com

Pros

Addressing high unmet medical need in neurology

Proprietary drug candidate intellectual property protection

Potential for orphan drug market exclusivity

Scalability of research platform across indications

Future licensing and partnership revenue potential

Cons

Extremely high capital intensity for drug development

High clinical trial failure rates for novel therapies

Extensive regulatory approval process uncertainty

Reliance on limited product pipeline success

Future competition from established pharmaceutical companies

NRSN Stock AI Analysis